Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic (18F-FDG PET/CT) Findings and Correlation with Clinico-Pathological and Survival Results

Rapicetta, Cristian; Lococo, Filippo; Stefani, Alessandro; Rossi, Giulio; Ricchetti, Tommaso; Filice, Angelina; Franceschetto, Antonella; Treglia, Giorgio; Paci, Massimiliano

doi:10.1007/s00408-016-9904-1

Cited by 17 publications

(14 citation statements)

References 15 publications

(18 reference statements)

Supporting

Mentioning

Contrasting

Unclassified

Order By: Relevance

“…In our study, the presence of a cavity remained as an important SRS model; however, the semantic feature was removed from the list of CRS model. We cannot explain exquisitely the difference in results between our study and the previous one [ 10 ]. But the multivariate nature of our radiomics or combined model, not univariate nature, might help explain the difference in the results.…”

Section: Discussioncontrasting

confidence: 99%

“…The total lesion glycolysis (TLG) of the primary tumor and KRAS mutation were independent prognostic factors of PCs [ 9 ]. In an additional PET/CT study [ 10 ], tumor SUVmax was not different in terms of tumor dimensions, histology, pathological stage, and pattern of recurrence. Pathologic stage, surgical completeness, and the presence of vascular or lymphatic invasion were related factors for patient survival.…”

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Pleomorphic carcinoma of the lung: Prognostic models of semantic, radiomics and combined features from CT and PET/CT in 85 patients

Kim

Cho

Choi

et al. 2021

European Journal of Radiology Open

View full text Add to dashboard Cite

To demonstrate semantic, radiomics, and the combined risk models related to the prognoses of pulmonary pleomorphic carcinomas (PCs). Methods: We included 85 patients (M:F = 71:14; age, 35-88 [mean, 63 years]) whose imaging features were divided into training (n = 60) and test (n = 25) sets. Nineteen semantic and 142 radiomics features related to tumors were computed. Semantic risk score (SRS) model was built using the Cox-least absolute shrinkage and selection operator (LASSO) approach. Radiomics risk score (RRS) from CT and PET features and combined risk score (CRS) adopting both semantic and radiomics features were also constructed. Risk groups were stratified by the median of the risk scores of the training set. Survival analysis was conducted with the Kaplan-Meier plots. Results: Of 85 PCs, adenocarcinoma was the most common epithelial component found in 63 (73 %) tumors. In SRS model, four features were stratified into high-and low-risk groups (HR, 4.119; concordance index ([Cindex], 0.664) in the test set. In RRS model, five features helped improve the stratification (HR, 3.716; C-index, 0.591) and in CRS model, three features helped perform the best stratification (HR, 4.795; C-index, 0.617). The two significant features of CRS models were the SUVmax and the histogram feature of energy ([CT Firstorder Energy]). Conclusion:In PCs of the lungs, the combined model leveraging semantic and radiomics features provides a better prognosis compared to using semantic and radiomics features separately. The high SUVmax of solid portion (CT Firstorder Energy) of tumors is associated with poor prognosis in lung PCs.

show abstract

Section: Discussioncontrasting

confidence: 99%

Section: Introductionmentioning

confidence: 99%

Pleomorphic carcinoma of the lung: Prognostic models of semantic, radiomics and combined features from CT and PET/CT in 85 patients

Kim

Cho

Choi

et al. 2021

European Journal of Radiology Open

View full text Add to dashboard Cite

show abstract

“…The majority of patients who had metastatic disease had poor PS and the proportion of patients who received first-line or subsequent lines of therapy was low, which reflects the aggressive disease biology. We found that the median SUV max of the tumour on the baseline PET-CT was 20.2, which is similar to that reported in other studies which reported that PSC has intense SUV uptake values [28,29]. This suggests that PSCs are F-fluorodeoxyglucose (FDG)-avid tumours and that performing a PET-CT scan would be an appropriate staging test, especially in patients who are being planned for radical therapy.…”

Section: Discussionsupporting

confidence: 87%

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre

Bondili¹,

Nandhana²,

Dhanawat³

et al. 2022

ecancer

View full text Add to dashboard Cite

show abstract

“…41 At imaging studies, PSC may present as either a central or peripheral location. 2,5,24,42 Pleomorphic carcinomas with squamous cell carcinoma component and carcinosarcoma may show a peculiar endobronchial, polypoid appearance ( Figure 2), while peripheral PSC typically manifests as a large mass (over 10 cm) with rounded, well-defined margins (Figures 3 and 4) with necrotic and/or hemorrhagic areas and soft surface with/without cavitation ( Figure 5).…”

Section: Epidemiology Imaging Studies Clinical Featuresmentioning

confidence: 99%

<p>Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma</p>

Baldovini¹,

Rossi²,

Ciarrocchi³

2019

LCTT

Self Cite

View full text Add to dashboard Cite

Pulmonary sarcomatoid carcinoma (PSC) is a heterogeneous category of primary lung cancer accounting from 0.3% to 3% of all primary lung malignancies. According to the most recent 2015 World Health Organization (WHO) classification, PSC includes several different variants of malignant epithelial tumors (carcinomas) histologically mimicking sarcomas showing or entirely lacking a conventional component of non-small cell lung cancer (NSCLC). Thus, this rare subheading of lung neoplasms includes pleomorphic carcinoma, spindle cell carcinoma, giant cell carcinoma, pulmonary blastoma, and carcinosarcoma. A diagnosis of PSC may be suspected on small biopsy or cytology, but commonly requires a surgical resection to reach a conclusive definition. The majority of patients with PSC consists of elderly, smoking men with a large, peripheral mass characterized by well-defined margins. However, presentation with a central, polypoid endobronchial lesion is well-documented, particularly in pleomorphic carcinoma and carcinosarcoma showing a squamous cell carcinoma component. As expected, PSC may pose diagnostic problems and immunohistochemistry is largely used when pathologists deal these tumors in routine practice. Indeed, PSC tends to overexpress molecules associated with the epithelial-to-mesenchymal transition, such as vimentin, but the panel of immunostains also includes epithelial markers (cytokeratins, EMA), TTF-1, p40 and negative markers (e.g., melanocytic, mesothelial and sarcoma-related primary antibodies). Although rare, PSC has increased their interest among oncologist community for different reasons: a. identification of the epithelial-to-mesenchymal phenomenon as a major mechanism of secondary resistance to tyrosine kinase inhibitors; b. over-expression of PD-L1 and effective treatment with immunotherapy; c. identification of c-MET exon 14 skipping mutation representing an effective target to crizotinib and other specific inhibitors. In this review, the feasibility of the diagnosis of PSC, its differential diagnosis and novel molecular findings characterizing this group of lung tumor are discussed.

show abstract

Primary Sarcomatoid Carcinoma of the Lung: Radiometabolic (18F-FDG PET/CT) Findings and Correlation with Clinico-Pathological and Survival Results

Abstract: No differences in terms of SUVmax were found with regard to tumour dimensions, histology (pure vs mixed, pleomorphic vs others), pathological stage and pattern of recurrence. P-stage, surgical radicality, vascular/lymphatic invasion but not SUVmax affected long-term survival in PSC.

Cited by 17 publications

References 15 publications

Pleomorphic carcinoma of the lung: Prognostic models of semantic, radiomics and combined features from CT and PET/CT in 85 patients

Pleomorphic carcinoma of the lung: Prognostic models of semantic, radiomics and combined features from CT and PET/CT in 85 patients

Characteristics and clinical outcomes of pulmonary sarcomatoid carcinoma: experience from Tata Memorial Centre

<p>Approaches to Tumor Classification in Pulmonary Sarcomatoid Carcinoma</p>

Contact Info

Product

Resources

About